Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Fisetin.
Fisetin is a flavonol senolytic that selectively induces apoptosis in senescent cells via inhibition of the PI3K/AKT/mTOR pathway and modulation of the SIRT1/AMPK axis to mitigate age-related systemic inflammation.
5281614
286.24 g/mol
2
2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Fisetin across standard consumer modalities.
Low aqueous solubility and rapid first-pass metabolism necessitate the use of lipid-based carriers or micronization to ensure therapeutic plasma concentrations.
The intense yellow pigment of fisetin can cause significant staining of manufacturing equipment and may require high concentrations of masking agents to offset its astringent polyphenolic profile.
The high therapeutic dose required for senolytic protocols exceeds the typical 20-40mg payload capacity of standard thin-film polymer matrices.
Ready to launch a product featuring Fisetin? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Fisetin extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Fisetin payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation